Validation of a semiconductor next-generation sequencing assay for the clinical genetic screening of CFTR.
Ontology highlight
ABSTRACT: Genetic testing for cystic fibrosis and CFTR-related disorders mostly relies on laborious molecular tools that use Sanger sequencing to scan for mutations in the CFTR gene. We have explored a more efficient genetic screening strategy based on next-generation sequencing (NGS) of the CFTR gene. We validated this approach in a cohort of 177 patients with previously known CFTR mutations and polymorphisms. Genomic DNA was amplified using the Ion AmpliSeq™ CFTR panel. The DNA libraries were pooled, barcoded, and sequenced using an Ion Torrent PGM sequencer. The combination of different robust bioinformatics tools allowed us to detect previously known pathogenic mutations and polymorphisms in the 177 samples, without detecting spurious pathogenic calls. In summary, the assay achieves a sensitivit
SUBMITTER: Trujillano D
PROVIDER: S-EPMC4585447 | biostudies-literature | 2015 Sep
REPOSITORIES: biostudies-literature
ACCESS DATA